Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients

@article{Dentali2007MetaanalysisAP,
  title={Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients},
  author={Francesco Dentali and James D Douketis and Monica Gianni and Wendy Lim and Mark Andrew Crowther},
  journal={Annals of Internal Medicine},
  year={2007},
  volume={146},
  pages={278-288}
}
Context Anticoagulant prophylaxis of venous thromboembolism in hospitalized patients is better established in surgical practice than in medical practice, in part because of the lack of convincing clinical trial evidence in hospitalized medical patients. Contributions The authors found 9 controlled, randomized trials of currently recommended unfractionated heparin or low-molecular-weight heparin prophylaxis regimens in hospitalized medical patients. Prophylaxis decreased the rate of pulmonary… Expand

Paper Mentions

Interventional Clinical Trial
Hospitalized trauma patients frequently suffer from blood clots in the legs or lungs. To minimize the risk of these blood clots developing, patients may be given a blood-thinner drug… Expand
ConditionsVenous Thromboembolism
InterventionDrug
Interventional Clinical Trial
Venous thromboemboli (VTE) are abnormal blood clots that commonly form in the blood vessels of the legs or lungs. They can block normal blood flow, damage organs, and even cause death… Expand
ConditionsVenous Thromboembolism
InterventionBehavioral, Other
Improved venous thromboembolism prophylaxis by pharmacist-driven interventions in acutely ill medical patients in Belgium
TLDR
Pharmacist-driven interventions improved the proportion of acutely ill medical patients receiving VTE prophylaxis according to clinical practice guidelines and the benefit of the interventions was maintained after 1 year. Expand
Prophylaxis against venous thromboembolism in hospitalized medically ill patients: Update and practical approach.
  • R. Camden, S. Ludwig
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2014
TLDR
The use of study enrollment criteria and patient demographics, including special population considerations, can provide guidance for risk determination and allow for an evidence-based approach to identifying eligible patients for prophylaxis. Expand
Evaluation of the use of venous thromboembolism prophylaxis in hospitalised medical patients.
TLDR
The provision rate of pharmacological VTE prophylaxis in hospitalised medical patients who met pre-defined clinical criteria for proplylaxis was 54% and increased with additional VTE risk factors to a peak rate of 67%. Expand
Mechanical prophylaxis of venous thromboembolism in ill hospitalized medical patients: evidence and guidelines
TLDR
The aim of this review is to focus on mechanical prophylaxis of VTE in hospitalized ill medical patients and to increase doubts and reduce certainness in this context. Expand
Deep vein thrombosis prophylaxis in hospitalized medical patients: current recommendations, general rates of implementation, and initiatives for improvement.
TLDR
Identifying medical patients at risk for VTE and providing effective prophylaxis is now an important health care priority to reduce the burden of this morbid and sometimes fatal disease. Expand
Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants
TLDR
Based on the results of recent studies, the new oral anticoagulants appear to have a very limited role, if any; however, a better risk stratification of patients who have a persistently increased risk of VTE is warranted to improve the risk to benefit profile of any antICOagulant drug to be used in this setting. Expand
Prophylaxis against venous thromboembolism in hospitalized medical patients: an evidence-based and practical approach.
TLDR
Among hospitalized medical patients, randomized trials have established an acceptable therapeutic benefit-to-risk ratio of anticoagulant prophylaxis to reduce the incidence of clinically silent and symptomatic venous thromboembolism, including a reduction inThe incidence of fatal PE. Expand
Identification of residual risk factors for the development of venous thromboembolism in medical inpatients receiving subcutaneous heparin therapy for prophylaxis
TLDR
Among hospitalized patients admitted to the medicine service and receiving VTE prophylaxis with subcutaneous unfractionated heparin, those with a previous history of VTE were at a significant risk of developing in-hospital VTE. Expand
Prevention of venous thromboembolism in the hospitalized medical patient.
TLDR
Based on results from the recently reported EXCLAIM trial, extended postdischarge prophylaxis with LMWH for 28 days should be considered for hospitalized medical patients with reduced mobility who are older than age 75 or have a cancer diagnosis or a history of VTE. Expand
Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions
  • J. Douketis
  • Medicine
  • Current opinion in pulmonary medicine
  • 2008
TLDR
Among hospitalized medical patients, randomized trials have established an acceptable therapeutic benefit-to-risk ratio of anticoagulant prophylaxis to reduce the incidence of clinically silent and symptomatic venous thromboembolism, including a reduction inThe incidence of fatal pulmonary embolism. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.
TLDR
Efforts should be made to elucidate the reasons that underlie the very low rate of thromboprophylaxis in medical patients and to develop and test strategies to improve implementation of this patient safety practice. Expand
The prophylaxis of medical patients for thromboembolism pilot study.
TLDR
The pilot study indicated that the full study was not feasible, and the effect of low-dose heparin prophylaxis on clinical outcomes in hospitalized general medical patients remains uncertain. Expand
Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases
TLDR
The findings do not support the routine use of heparin prophylaxis for 3 weeks or less in large groups of non-surgical patients, and further studies are needed to investigate whether heparins of longer duration may prevent fatal pulmonary embolism. Expand
Heparin Prophylaxis for Medical Patients?
TLDR
Low-dose heparin prophylaxis has been recommended for hospitalized medical patients with risk factors for thromboembolism, which include advanced age, prolonged immobility or paralysis, stroke, myocardial infarction, congestive heart failure, chest infections, cancer, hypercoagulable states, inflammatory bowel disease, estrogen therapy, and need for intensive care. Expand
Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.
TLDR
This meta-analysis of randomised trials studying prophylactic unfractionated and low-molecular-weight heparin in internal medicine shows that heparins are beneficial in the prevention of venous thromboembolism in internal Medicine. Expand
Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients.
TLDR
Routine practices in the prevention of VTE in high-risk surgical patients are examined to determine the extent of adoption of grade A prophylactic therapies as recommended by the American College of Chest Physicians. Expand
Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group.
TLDR
The findings do not support the routine use of heparin prophylaxis for 3 weeks or less in large groups of non-surgical patients and further studies are needed to investigate whether heparins of longer duration may prevent fatal pulmonary embolism. Expand
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.
TLDR
The primary univariate analysis showed that the presence of an acute infectious disease, age older than 75 years, cancer, and a history of VTE were statistically significantly associated with an increased VTE risk. Expand
Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
TLDR
Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding and was maintained at 90 days. Expand
Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
TLDR
The MEDENOX trial demonstrated that prophylaxis with enoxaparin substantially decreases the risk of VTE among acutely ill, hospitalized medical patients, and economic analysis indicates that this protection represents a small increase in current treatment costs. Expand
...
1
2
3
4
5
...